18 February 2018
News and Views
Links and Services
A study in this month's issue of the American Journal of Gastroenterology reviews the efficacy and safety of rifaximin for the irritable bowel syndrome.
Irritable bowel syndrome (IBS) affects 10–15% of the population, and treatment options are limite
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors